Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System
Completed · Phase 2
Conditions studied: Neurodegenerative Disease, Parkinson's Disease
In brief
This study is designed to determine whether dextromethorphan, a drug commonly found in cough medicine, is beneficial and safe for the treatment of Parkinson's disease and other diseases that might share biochemical abnormalities with Parkinson's disease. Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Rhythmical muscular tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease. Researchers believe that dextromethorphan may be able to safely modify psychomotor function of patients with Parkinson's Disease.
Key facts
- Study ID
- NCT00001365
- Run by
- National Institute of Neurological Disorders and Stroke (NINDS)
- People needed
- 42
- Starts
- 1993-07-01
- Expected to finish
- 2001-06-01
- Last updated by the study team
- 2006-07-13
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- National Institute of Neurological Disorders and Stroke (NINDS) — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.